BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Cheng Y, Tang R, Li X, Wang B, Cheng Y, Xiao S, Sun P, Yu W, Li C, Lin X, Zhu Y. LRP1B is a Potential Biomarker for Tumor Immunogenicity and Prognosis of HCC Patients Receiving ICI Treatment. JHC 2022;Volume 9:203-20. [DOI: 10.2147/jhc.s348785] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
Number Citing Articles
1 Xu F, Cui WQ, Liu C, Feng F, Liu R, Zhang J, Sun CG. Prognostic biomarkers correlated with immune infiltration in non-small cell lung cancer. FEBS Open Bio 2023;13:72-88. [PMID: 36282125 DOI: 10.1002/2211-5463.13501] [Reference Citation Analysis]
2 Conconi D, Jemma A, Giambra M, Redaelli S, Croci GA, Dalprà L, Lavitrano M, Bentivegna A. Analysis of copy number alterations in bladder cancer stem cells revealed a prognostic role of LRP1B. World J Urol 2022. [PMID: 35841413 DOI: 10.1007/s00345-022-04093-1] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
3 Yu G, Mu H, Fang F, Zhou H, Li H, Wu Q, Xiong Q, Cui Y. LRP1B mutation associates with increased tumor mutation burden and inferior prognosis in liver hepatocellular carcinoma. Medicine (Baltimore) 2022;101:e29763. [PMID: 35777027 DOI: 10.1097/MD.0000000000029763] [Reference Citation Analysis]